A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study

NCT06290505 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

54

Enrollment

NETWORK

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Durvalumab

Sponsor

Australasian Gastro-Intestinal Trials Group